Millicom (Tigo) reports continued strength in Q1
Millicom (Tigo) reports continued strength in Q1
Luxembourg, April28, 2022– Millicom is pleased to announce its first quarter 2022 results. Please find below links to the Q1 2022 Earnings Release, and IAS 34 Interim Condensed Consolidated Financial Statements.
Millicom Chief Executive Officer Mauricio Ramos commented:
"We are off to a strong start in 2022, with operating and financial results ahead of our plans. Our Mobile business performed particularly well, especially in Colombia, where we have added one million postpaid subscribers over the past 12 months, implying growth of more than 50% in the country, and puts us well on track toward achieving the scale we need to sustain higher levels of profitability in that market over the long term.
B2B also performed strongly, with growth accelerating to about 5%, our fastest growth in morethan three years. Thisis a direct result of our strategic focus in this area in recent years. Asdiscussed at the recent Investor Day, we havesimplified our product set around clear customer segments, and we have invested to develop the technical salescapabilities needed to meet thestrong demand for cloud and other digital services. Meanwhile, Home continued toperform strongly, with solid net adds and service revenue growth of just over 5% as compared to a very strong Q1 in2021. We anticipate faster growth in H2 2022, as we ramp up our planned network expansion toward our goal ofadding approximately 1 million new homes passed in 2022.
We continued to develop Tigo Money, our Fintech business, boosting our commercial efforts in Guatemala andreadying the Panama launch later this year, and we are advancing with the plans outlined at our recent Investor Dayto unlock value from both our Tigo Money and our Infrastructure businesses.
Finally, I am pleased to report that we have once again ranked as the top telco in the region in the 2022 Great Place toWork survey, placing in the Top 5 in eight of our nine countries and #5 in Central America across all industries.
Based on the broad-based nature of our solid performance in Q1, I am confident that 2022 will be an outstanding year for Millicom, now entirely focused on the Latin America region."
Video conferencecall details
A video conference to discuss these results will take place on April 28, 2022 at 14:00 (Stockholm) | 13:00 (London) | 08:00 (Miami).
Registration for the interactive event is required at the following link.
After registering, participants will receive a confirmation email containing details about joining the video conference. Participants who wish to ask a question during the live event must notify the Investor Relations team via email to firstname.lastname@example.org after the start of the event.
Participants may also join the conference in listen-only mode by dialling any of the following numbers and entering the Webinar ID: 813 9817 2391:
US: +1 929 205 6099Sweden: +46 850 539 728
UK: +44 330 088 5830Luxembourg: +352 342 080 9265
Additional international numbers are available at the following link.
For further information, please contact
Yocasta Valdez, Group Manager Digital Media & Communications
Sarah Inmon, Director Investor Relations
Michel Morin, VP Investor Relations
Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile telecommunications services in Latin America. Through our TIGO® and Tigo Business® brands, we provide a wide range of digital services and products, including TIGO Money for mobile financial services, TIGO Sports for local entertainment, TIGO ONEtv for pay TV, high-speed data, voice, and business-to-business solutions such as cloud and security. As of March 31, 2022, Millicom employed approximately 20,000 people and provided mobile and fiber-cable services through its digital highways to around 50 million customers, with a fiber-cable footprint of close to 13 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg.
This information was prior to this release inside information and is information that Millicom is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on April 28, 2022.
- Millicom - Earnings Release - Q1 2022
- Millicom - IAS34 - Q1 2022
- PR_Millicom (Tigo) reports continued strength in Q1 2022_042822
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse
KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek
Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a
XPENG Oslo Experience Store Now Open With XPENG G3i and XPENG P5 Available for Local Test Drives19.5.2022 11:00:00 CEST | Press release
XPENG opens its first Brand Experience Store in the Bjørvika area of downtown Oslo on May 19, 2022.The launch of the fully electric XPENG P5 and XPENG G3i makes Norway the first European country to boast the full range of XPENG EVs. Local test drives are now available to customers.XPENG, in June this year, will be participating in the 35th International Electric Vehicle Symposium (EVS35) 2022, the world’s largest international EV event live from Oslo. OSLO, Norway, May 19, 2022 (GLOBE NEWSWIRE) -- XPENG, a leading electric vehicle manufacturer, is taking the next step in its European expansion by opening its first Norwegian Brand Experience Store in the Bjørvika area of Oslo on May 19. This coincides with the official launch of the brand's two latest models, XPENG G3i and XPENG P5. Establishing a Local Presence XPENG is one of the early adopters of a disruptive retail model in the European market, combining direct, in-store sales with wider agency collaboration. In the Oslo Brand Exper
IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release
Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed
Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral